Company

Asmacure Ltée

As of the edition of 20 October 2026, Asmacure Ltée runs 1 drug; it is on route A at 5 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Family history

Asmacure Ltée was merged.

  • Asmacure Ltée: merged

Drugs by status

StatusCount
Stopped1
Total1

Where it needs a new molecule

Route A at 5 targets, route B at 0 targets.

Three of its 5 rows, by target and route
TargetRoute
CHRNA3 Neuronal acetylcholine receptor subunit alpha-3Route A
CHRM2 Muscarinic acetylcholine receptor M2Route A
CHRM3 Muscarinic acetylcholine receptor M3Route A

All 5 rows on route A or B

In the product

5 company-target rows on route A or B; 2 are not shown here, and no score is.

Where its trials are

  • Lungs and airways: 3 trials led
  • Immune system: 2 trials led